KORU Medical Systems vs TriSalus Life Sciences
KRMD and TLSI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRMD and TLSI compare
KORU Medical Systems and TriSalus Life Sciences are about the same size, with market caps of $161M and $141M.
TriSalus Life Sciences grew revenue faster over the last twelve months (25.2% versus 22.4% for KORU Medical Systems).
KORU Medical Systems keeps more of each dollar of sales as profit, with a net margin of −4.0% compared with −62.6% at TriSalus Life Sciences.
KORU Medical Systems scores higher on the StockData Score (12 against 5 for TriSalus Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRMD | TLSI |
|---|---|---|
| Size and price | ||
| Market cap | $161M | $141M |
| Share price | $3.49 | $2.29 |
| Change, 1 year | −19.2% | −49.7% |
| Change, 5 years | −4.4% | −77.0% |
| Beta (5Y) | 1.09 | 2.29 |
| Employees | 73 | 102 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× | 3.1× (better) |
| P/B | 8.9× (better) | 21.6× |
| P/FCF | 207× | – |
| FCF yield | 0.48% (better) | −16.5% |
| Fair value | $2.67 | – |
| Margin of safety | −30.9% | – |
| Growth | ||
| Revenue growth (TTM) | 22.4% | 25.2% (better) |
| Revenue growth, 5Y average | 11.2% | – |
| Profitability | ||
| Gross margin | 62.4% | 85.8% (better) |
| Operating margin | −3.7% (better) | −67.7% |
| Net margin | −4.0% (better) | −62.6% |
| FCF margin | 1.7% (better) | −51.6% |
| Return on equity | −10.5% | – |
| Return on invested capital | −14.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | 5.05 (better) |
| Interest coverage | – | −5.2× |
| Current ratio | 2.72 | 5.35 (better) |
| Altman Z-score | 10.07 (better) | −6.02 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −31.3% |
| Shareholder yield | 0.00% (better) | −31.3% |
| Ownership | ||
| Held by institutions | 44.5% | 38.6% |
| Held by insiders | 17.6% | 29.7% |
| Insider net buying, 12 months | $1.6M | $3.6M (better) |
| Short interest, % of float | 2.3% | – |
Go deeper
- KRMD stock overview
- KRMD income statement
- KRMD valuation and score
- TLSI stock overview
- TLSI income statement
- TLSI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.